Sažetak sa skupa

BIOMARKERS IN AXIAL SPONDYLOARTHRITIS

Kristyna Bubova ; Odjel za reumatologiju, I. Medicinski fakultet, Karlovo sveučilište i Institut za reumatologiju
Ladislav Senolt ; Odjel za reumatologiju, I. Medicinski fakultet, Karlovo sveučilište i Institut za reumatologiju

Sažetak

Axial spondyloarthritis (axSpA) is a common chronic inflammatory rheumatic disease affecting predominantly axial skeleton. Long-term duration of the disease causes bone erosions, new bone formation and can gradually lead to ankylosis of the joints. Despite new possibilities for detection of early disease, the delay from the occurrence of the first symptom(s) to the diagnosis is still striking. Recent studies have focused on biomarkers that would help to diagnose the disease earlier, to determine disease activity and to select patients with potential rapid
progression. To this date the only widely used biomarker with some diagnostic value is HLA-B27 antigen. Other potential biomarkers can be found among acute-phase reactants. Some of them have been already
well studied (calprotec tin, IL-27), however some are newly discovered (defensin-2, lipocalin-2). Recently even relations between biomarkers of fat metabolism (triglycerides, glycerol) and fatty MRI lesions were studied for diagnostic utility. Second presented group could be entitled as disease activity biomarkers, where C-reactive protein (CRP) together
with active magnetic resonance imaging (MRI) lesions are used as common indicators of disease activity. Other inflammatory biomarkers are serum amyloid A, some interleukins and tissue turnover biomarkers (metalloproteinases and their products of degradation). The last part of the presentation will be related to prognostic biomarkers. Except for already mentioned biomarkers (e.g. CRP or MMPs), vasoactive endothelial growth factor (VEGF) together with vimentin fragments, biomarkers of bone remodelling (DKK-1 and sclerostin) and some adipokines have been found to predict radiographic progression. Recently altered microRNAs (miRNAs) expression and target gene dysregulation have been shown to potentially predict progression of the disease. Several biomarkers have been identified as potential diagnostic candidates, disease activity reflectors or markers of disease prognosis. The problem of inadequate sensitivity and specificity of these biomarkers however still remains and therefore future studies are needed for further validation.
References:
1. Walter P. Maksymowych (2017) An update on biomarker discovery and use in axial spondyloarthritis,Expert Review of Molecular
Diagnostics, 17:11, 965–974
2. Prajzlerova K, Grobelna K, Pavelka K, et al. An update on biomarkers in axial spondyloarthritis. Autoimmunity reviews 2016 doi:
10.1016/j.autrev.2016.02.002
3. Mattey DL, Packham JC, Nixon NB, et al. Association of cytokine and matrix metalloproteinase profi les with disease activity and
function in ankylosing spondylitis. Arthritis Res Th er 2012; 14(3): R127.
4. Taylan A, Sari I, Akinci B, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing
spondylitis. BMC Musculoskelet Disord 2012;13:191. doi: 10.1186/1471-2474-13-191
5. Baraliakos X, Landewe R, Heijde DVD, et al. Th e Relationship of Biomarkers and Radiographic Progression in Patients with Ankylosing
Spondylitis. Arthritis and rheumatism 2010;62(10):105.

Ključne riječi

Hrčak ID:

212215

URI

https://hrcak.srce.hr/212215

Datum izdavanja:

5.12.2018.

Posjeta: 1.367 *